Entero Therapeutics, Inc.
ENTO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8 | $6 | $7 | $9 |
| - Cash | $3 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $7 | $7 | $8 | $9 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$1 | -$1 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.75 | -0.21 | -0.28 | -2.57 |
| % Growth | -257.1% | 25% | 89.1% | – |
| Operating Cash Flow | -$1 | -$0 | -$1 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$0 | -$1 | -$0 |